FP
Flagship Pioneering Portfolio holdings
AUM
$268M
This Quarter Return
-17.17%
1 Year Return
-54.4%
3 Year Return
-51.2%
5 Year Return
+66.7%
10 Year Return
–
AUM
$394M
AUM Growth
+$394M
(+32%)
Cap. Flow
+$175M
Cap. Flow
% of AUM
44.35%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
2
Increased
–
Reduced
–
Closed
1
Top Buys
| 1 |
Denali Therapeutics
DNLI
|
$139M |
| 2 |
Quanterix
QTRX
|
$43.6M |
Top Sells
| 1 |
TTOO
T2 Biosystems, Inc
TTOO
|
$8.19M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Denali Therapeutics
DNLI
$2.23B
| $139M | 35.37% |
+8,918,749
| New | +$139M |
|
2
Seres Therapeutics
MCRB
$166M
| $129M | 32.61% |
12,682,876
| – | – |
|
3
Editas Medicine
EDIT
$231M
| $51.5M | 13.05% |
1,674,435
| – | – |
|
|
4
Quanterix
QTRX
$211M
| $43.6M | 11.06% |
+2,030,495
| New | +$43.6M |
|
|
SYRS
5
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $31.2M | 7.91% |
3,204,437
| – | – |
|
|
TTOO
6
DELISTED
T2 Biosystems, Inc
TTOO
| – | – |
-1,950,583
| Closed | -$8.19M |
|